NVAX · Novavax Inc · Documents

$8.76 -1.22 (-12.22%) At close · Nov 12 Play latest call Q2 2026 earnings call transcript

Russell 2000 member Rebalance outlook locked

Market Cap

$1.45B

165.01M

Volume · Nov 12 7.01M Avg daily vol (3M) 6.74M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $1.12B up 64.7% 10-K filed Feb 26, 2026 Quarterly report FY2026 Q3 Revenue $68.3M down 3.0% 10-Q filed Nov 5, 2026 Latest results Financial results 8-K filed Nov 5, 2026 Earnings call Q2 2026 earnings call Held Aug 6, 2026

2026

Nov 5

Quarterly report 10-Q FY2026 Q3, ended Sep 30

Quarterly net loss narrows sharply as research spending falls

Novavax reported revenue of $68.3 million and a net loss of $31.4 million, or $0.19 per share, for the three months ended September 30, 2026, versus a $202.4 million loss, or $1.25 per share, in 2025. R&D expenses fell to $52.4 million from $98.3 million.

Revenue $68.3M ▼ 3.0% Net loss $31.38M Diluted EPS -$0.19

Read from the MD&A section

4 source passages

Novavax tackles some of the world’s most significant health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M® adjuvant and protein-based nanoparticles. Revenue for the three months ended September 30, 2026 was $68.3 million as compared to $70.4 million for the same period in 2025, a decrease of $2.1 million. Net loss for the three months ended September 30, 2026 was $31.4 million, or $0.19 per share, basic and diluted, as compared to a net loss of $202.4 million, or $1.25 per share, basic and diluted, for the same period in 2025. Research and development expenses were $52.4 million for the three months ended September 30, 2026 as compared to $98.3 million for the three months ended September 30, 2025, a decrease of $45.8 million. Open the document at this passage

Nov 5

Current report 8-K

Financial results AI summary on its way

Oct 29

Current report 8-K

Sanofi trial dosing triggers $125 million milestone

Sanofi dosed the fifth patient on October 28, 2026 in its Phase 3 influenza-COVID-19 combination vaccine trial in the European Union, triggering a $125 million milestone payment to Novavax expected by the first quarter of 2027.

Regulation FD disclosure, Other events

3 source passages

On October 28, 2026 Sanofi Pasteur Inc. (“Sanofi”) dosed the fifth patient in its Phase 3 influenza-COVID-19 combination vaccine trial in the European Union, utilizing the Company’s COVID-19 component. Dosing of the fifth patient has triggered a $125 million milestone payment from Sanofi under the Company’s Collaboration and License Agreement with Sanofi. The Company anticipates receipt of payment by the first quarter of 2027. Open the document at this passage

Sep 10

Investor event

Citi’s 2026 BioPharma Back to School Conference AI summary on its way

Aug 6

Earnings call

Q2 2026 earnings call AI summary on its way

Aug 6

Current report 8-K

Financial results AI summary on its way

Aug 6

Quarterly report 10-Q FY2026 Q2, ended Jun 30

Quarterly report for FY2026 Q2 AI summary on its way